COMPARE · Data as of August 21, 2026
ALC vs DXCM
Verdict: Side-by-side breakdown using the Bull Rankings model. ALC scored 73.3, DXCM scored 77.5 — DXCM leads.
Compare another set
ALC
Alcon Inc.
73.3
$73.63 · $35.6B
Score gap
4.2
DXCM leads
DXCM
DexCom, Inc.
77.5
$92.34 · $34.8B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestDXCM36.5x
- Fastest growthDXCM+15.5%
- Strongest balance sheetALC0.25
- Highest qualityDXCM91 / 100
- Largest discount to fair valueALC-30%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
ALC
stronger →← stronger
DXCM
87
Qualityreturns · margins · balance sheet
91
71
Growthrevenue & earnings expansion
89
63
Valuevaluation vs sector peers
58
DXCM is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ALC
DXCM
$2.1bB
FCF
$1.4bC+
+10.5%B
Rev
+15.5%B+
0.25B
D/E
0.53B
56.2xC
P/E
36.5xC+
1.53C+
PEG
1.70C+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ALC
DXCM
30% below
Price vs fair valuelower is cheaper
64% above
~0%/yr
Growth the price implies10-yr FCF · lower = less priced in
~24%/yr
+24%
1-yr DCF upside
-49%
+43%
5-yr DCF upside
-39%
+76%
10-yr DCF upside
-22%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ALC
Why this score
- Durable high returns
DXCM
Why this score
- Buying back stock
- Durable high returns
The companies
ALCAlcon Inc.
Why now
Medical Instruments & Supplies · market cap $35.6b. 16% off the 52-week high of $87.64. Revenue growing +10%, comfortably above the S&P median. 15 sell-side analysts rate this a Buy with a mean 1-yr target of $85.24 (implying +16% upside).
Moat
Net margin 31% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 30% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk
Trailing P/E 56.2x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating.
DXCMDexCom, Inc.
Why now
Medical Devices · market cap $34.8b. Trading near 52-week high of $92.56 — momentum setup, limited technical margin of safety. Revenue growing +16%, comfortably above the S&P median. 25 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $94.12 (implying +2% upside).
Moat
Net margin 20% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 38% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 141% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trading within 0% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Beta 1.41 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 36x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ALC and DXCM diverge
On the headline score the gap is 4.2 points in favor of DXCM. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- GrowthALC 71.4 · DXCM 89.5DXCM +18.1
- ValueALC 63.2 · DXCM 57.6ALC +5.6
- QualityALC 87.5 · DXCM 90.6DXCM +3.1
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.